Health Canada approves Nuvaxovid a vaccine to protect against COVID 19 infection.
Health Canada has approved Novavax Inc's COVID-19 vaccine, Nuvaxovid, for people aged 18 years and older, making it the fifth such vaccine to be cleared for use in Canada.
The vaccine's safety and effectiveness in people younger than 18 years have not yet been established.
Novavax's recombinant protein vaccine, Nuvaxovid, uses a more established technology than mRNA, the novel method behind the two most commonly used COVID-19 vaccines - from Pfizer - BioNTech and Moderna. About 80% of Canadians have received two doses of a COVID vaccine, and over 40% have also received a third or a booster shot.
Novavax Chief Commercial Officer John Trizzino said there is still significant demand for vaccination across the globe, especially in light of Omicron, the threat of more variants and a high percentage of unvaccinated people who need primary vaccination.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.